^
BCR-ABL1 fusion
|
CML
|
BCR-ABL1 fusion
|
CML
|
asciminib Sensitive: B - Late Trials
Novartis Press Release - 2 days (New B)
|
asciminib Sensitive: B - Late Trials
Novartis Press Release - 2 days - (New B)
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
venetoclax + ibrutinib Sensitive: B - Late Trials
Businesswire - 2 days (New B)
|
venetoclax + ibrutinib Sensitive: B - Late Trials
Businesswire - 2 days - (New B)
|
TP53 wild-type
|
CLL
|
TP53 wild-type
|
CLL
|
venetoclax Sensitive: A2 - Guideline
NICE - 1 week (New A2)
|
venetoclax Sensitive: A2 - Guideline
NICE - 1 week - (New A2)
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
venetoclax Sensitive: A1 - Approval
NICE - 1 week (New A1)
|
venetoclax Sensitive: A1 - Approval
NICE - 1 week - (New A2)
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
venetoclax Sensitive: A1 - Approval
NICE - 1 week (New A1)
|
venetoclax Sensitive: A1 - Approval
NICE - 1 week - (New A2)
|
TP53 mutation
|
AML
|
TP53 mutation
|
AML
|
DHODH inhibitor Sensitive: D – Preclinical
Cancer Res - 1 week (New D)
|
DHODH inhibitor Sensitive: D – Preclinical
Cancer Res - 1 week - (New D)
|
No biomarker
|
AML
|
No biomarker
|
AML
|
KRP-203 Sensitive: B - Late Trials
PRNewswire - 3 weeks (New B)
|
KRP-203 Sensitive: B - Late Trials
PRNewswire - 3 weeks - (New B)
|
CD20 positive
|
CLL
|
CD20 positive
|
CLL
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
gilteritinib Sensitive: A1 - Approval
|
gilteritinib Sensitive: A1 - Approval
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
enasidenib Sensitive: A1 - Approval
|
enasidenib Sensitive: A1 - Approval
|
No biomarker
|
AML
|
No biomarker
|
AML
|
glasdegib Sensitive: A1 - Approval
|
glasdegib Sensitive: A1 - Approval
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
rituximab + ibrutinib Sensitive: A1 - Approval
|
rituximab + ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
AML
|
No biomarker
|
AML
|
azacitidine oral Sensitive: A1 - Approval
|
azacitidine oral Sensitive: A1 - Approval
|
No biomarker
|
AML
|
No biomarker
|
AML
|
cytarabine/daunorubicin liposomal formulation Sensitive: A1 - Approval
|
cytarabine / daunorubicin liposomal formulation Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
BCR-ABL1 fusion
|
CML
|
BCR-ABL1 fusion
|
CML
|
dasatinib Sensitive: A1 - Approval
|
dasatinib Sensitive: A1 - Approval
|
BCR-ABL1 T315I
|
CML
|
BCR-ABL1 T315I
|
CML
|
asciminib Sensitive: A1 - Approval
|
asciminib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
orelabrutinib Sensitive: A1 - Approval
|
orelabrutinib Sensitive: A1 - Approval
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
midostaurin Sensitive: A1 - Approval
|
midostaurin Sensitive: A1 - Approval
|
CD33 positive
|
AML
|
CD33 positive
|
AML
|
gemtuzumab ozogamicin Sensitive: A1 - Approval
|
gemtuzumab ozogamicin Sensitive: A1 - Approval
|
BCR-ABL1 fusion
|
ALL
|
BCR-ABL1 fusion
|
ALL
|
imatinib Sensitive: A1 - Approval
|
imatinib Sensitive: A1 - Approval
|
No biomarker
|
CML
|
No biomarker
|
CML
|
omacetaxine mepesuccinate Sensitive: A1 - Approval
|
omacetaxine mepesuccinate Sensitive: A1 - Approval
|
CD22 positive
|
B Acute Lymphoblastic Leukemia
|
CD22 positive
|
B Acute Lymphoblastic Leukemia
|
inotuzumab ozogamicin Sensitive: A1 - Approval
|
inotuzumab ozogamicin Sensitive: A1 - Approval
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
inotuzumab ozogamicin Sensitive: A1 - Approval
|
inotuzumab ozogamicin Sensitive: A1 - Approval
|
CD20 expression
|
CLL
|
CD20 expression
|
CLL
|
rituximab-arrx Sensitive: A1 - Approval
|
rituximab-arrx Sensitive: A1 - Approval
|
BCR-ABL1 T315I
|
CML
|
BCR-ABL1 T315I
|
CML
|
ponatinib Sensitive: A1 - Approval
|
ponatinib Sensitive: A1 - Approval
|
BCR-ABL1 T315I
|
ALL
|
BCR-ABL1 T315I
|
ALL
|
ponatinib Sensitive: A1 - Approval
|
ponatinib Sensitive: A1 - Approval
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
blinatumomab Sensitive: A1 - Approval
|
blinatumomab Sensitive: A1 - Approval
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
blinatumomab Sensitive: A1 - Approval
|
blinatumomab Sensitive: A1 - Approval
|
No biomarker
|
AML
|
No biomarker
|
AML
|
venetoclax Sensitive: A1 - Approval
|
venetoclax Sensitive: A1 - Approval
|
No biomarker
|
CML
|
No biomarker
|
CML
|
ponatinib Sensitive: A1 - Approval
|
ponatinib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
Rixathon (rituximab biosimilar) Sensitive: A1 - Approval
|
Rixathon (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
venetoclax + rituximab Sensitive: A1 - Approval
|
venetoclax + rituximab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
zanubrutinib Sensitive: A1 - Approval
|
zanubrutinib Sensitive: A1 - Approval
|
BCR-ABL1 fusion
|
ALL
|
BCR-ABL1 fusion
|
ALL
|
ponatinib Sensitive: A1 - Approval
|
ponatinib Sensitive: A1 - Approval
|
ABL1 T315I
|
CML
|
ABL1 T315I
|
CML
|
ponatinib Sensitive: A1 - Approval
|
ponatinib Sensitive: A1 - Approval
|
Chr t(1;16)(q12;q11.2)
|
CML
|
Chr t(1;16)(q12;q11.2)
|
CML
|
ponatinib Sensitive: A1 - Approval
|
ponatinib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
ibrutinib Sensitive: A1 - Approval
|
ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
ibrutinib + obinutuzumab Sensitive: A1 - Approval
|
ibrutinib + obinutuzumab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
obinutuzumab Sensitive: A1 - Approval
|
obinutuzumab Sensitive: A1 - Approval
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
nelarabine Sensitive: A1 - Approval
|
nelarabine Sensitive: A1 - Approval
|
BCR-ABL1 fusion
|
ALL
|
BCR-ABL1 fusion
|
ALL
|
dasatinib Sensitive: A1 - Approval
|
dasatinib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
ofatumumab Sensitive: A1 - Approval
|
ofatumumab Sensitive: A1 - Approval
|
CD19 positive
|
ALL
|
CD19 positive
|
ALL
|
blinatumomab Sensitive: A1 - Approval
|
blinatumomab Sensitive: A1 - Approval
|
No biomarker
|
AML
|
No biomarker
|
AML
|
decitabine Sensitive: A1 - Approval
|
decitabine Sensitive: A1 - Approval
|
No biomarker
|
Hairy Cell Leukemia
|
No biomarker
|
Hairy Cell Leukemia
|
cladribine Sensitive: A1 - Approval
|
cladribine Sensitive: A1 - Approval
|
Chr t(15;17)
|
Acute Promyelocytic Leukemia
|
Chr t(15;17)
|
Acute Promyelocytic Leukemia
|
arsenic trioxide Sensitive: A1 - Approval
|
arsenic trioxide Sensitive: A1 - Approval
|
PML-RARA fusion
|
Acute Promyelocytic Leukemia
|
PML-RARA fusion
|
Acute Promyelocytic Leukemia
|
arsenic trioxide Sensitive: A1 - Approval
|
arsenic trioxide Sensitive: A1 - Approval
|
CD20 positive
|
CLL
|
CD20 positive
|
CLL
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
venetoclax Sensitive: A1 - Approval
|
venetoclax Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
rituximab/hyaluronidase Sensitive: A1 - Approval
|
rituximab / hyaluronidase Sensitive: A1 - Approval
|
No biomarker
|
CML
|
No biomarker
|
CML
|
busulfan Sensitive: A1 - Approval
|
busulfan Sensitive: A1 - Approval
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
mercaptopurine Sensitive: A1 - Approval
|
mercaptopurine Sensitive: A1 - Approval
|
No biomarker
|
AML
|
No biomarker
|
AML
|
azacitidine Sensitive: A1 - Approval
|
azacitidine Sensitive: A1 - Approval
|
No biomarker
|
CMML
|
No biomarker
|
CMML
|
azacitidine Sensitive: A1 - Approval
|
azacitidine Sensitive: A1 - Approval
|
BCR-ABL1 fusion
|
CML
|
BCR-ABL1 fusion
|
CML
|
nilotinib Sensitive: A1 - Approval
|
nilotinib Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
ibrutinib Sensitive: A1 - Approval
|
ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
obinutuzumab + acalabrutinib Sensitive: A1 - Approval
|
obinutuzumab + acalabrutinib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
obinutuzumab Sensitive: A1 - Approval
|
obinutuzumab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
acalabrutinib Sensitive: A1 - Approval
|
acalabrutinib Sensitive: A1 - Approval
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
ivosidenib Sensitive: A1 - Approval
|
ivosidenib Sensitive: A1 - Approval
|
BCR-ABL1 fusion
|
CML
|
BCR-ABL1 fusion
|
CML
|
bosutinib Sensitive: A1 - Approval
|
bosutinib Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
rituximab + idelalisib Sensitive: A1 - Approval
|
rituximab + idelalisib Sensitive: A1 - Approval
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
rituximab + idelalisib Sensitive: A1 - Approval
|
rituximab + idelalisib Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
acalabrutinib Sensitive: A1 - Approval
|
acalabrutinib Sensitive: A1 - Approval
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
acalabrutinib Sensitive: A1 - Approval
|
acalabrutinib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
alemtuzumab Sensitive: A1 - Approval
|
alemtuzumab Sensitive: A1 - Approval
|
BCR-ABL1 fusion
|
CML
|
BCR-ABL1 fusion
|
CML
|
imatinib Sensitive: A1 - Approval
|
imatinib Sensitive: A1 - Approval
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
vincristine liposomal Sensitive: A1 - Approval
|
vincristine liposomal Sensitive: A1 - Approval
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
blinatumomab Sensitive: A1 - Approval
|
blinatumomab Sensitive: A1 - Approval
|
No biomarker
|
Hairy Cell Leukemia
|
No biomarker
|
Hairy Cell Leukemia
|
moxetumomab pasudotox Sensitive: A1 - Approval
|
moxetumomab pasudotox Sensitive: A1 - Approval
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
blinatumomab Sensitive: A1 - Approval
|
blinatumomab Sensitive: A1 - Approval
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
idelalisib + ofatumumab Sensitive: A1 - Approval
|
idelalisib + ofatumumab Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
idelalisib + ofatumumab Sensitive: A1 - Approval
|
idelalisib + ofatumumab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
rituximab + idelalisib Sensitive: A1 - Approval
|
rituximab + idelalisib Sensitive: A1 - Approval
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
inotuzumab ozogamicin Sensitive: A1 - Approval
|
inotuzumab ozogamicin Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
duvelisib Sensitive: A1 - Approval
|
duvelisib Sensitive: A1 - Approval
|
No biomarker
|
CMML
|
No biomarker
|
CMML
|
decitabine/cedazuridine Sensitive: A1 - Approval
|
decitabine / cedazuridine Sensitive: A1 - Approval
|
No biomarker
|
AML
|
No biomarker
|
AML
|
idarubicin hydrochloride Sensitive: A1 - Approval
|
idarubicin hydrochloride Sensitive: A1 - Approval
|
CD20 positive
|
CLL
|
CD20 positive
|
CLL
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
BCR-ABL1 mutation
|
CML
|
BCR-ABL1 mutation
|
CML
|
asciminib Sensitive: A1 - Approval
|
asciminib Sensitive: A1 - Approval
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
brexucabtagene autoleucel Sensitive: A1 - Approval
|
brexucabtagene autoleucel Sensitive: A1 - Approval
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
recombinant Erwinia asparaginase Sensitive: A1 - Approval
|
recombinant Erwinia asparaginase Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
bendamustine Sensitive: A1 - Approval
|
bendamustine Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
bendamustine RTD Sensitive: A1 - Approval
|
bendamustine RTD Sensitive: A1 - Approval
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
pegaspargase Sensitive: A1 - Approval
|
pegaspargase Sensitive: A1 - Approval
|
CD20 positive
|
Childhood B Acute Lymphoblastic Leukemia
|
CD20 positive
|
Childhood B Acute Lymphoblastic Leukemia
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
No biomarker
|
Juvenile Myelomonocytic Leukemia
|
No biomarker
|
Juvenile Myelomonocytic Leukemia
|
azacitidine Sensitive: A1 - Approval
|
azacitidine Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
PCR Sensitive: A2 - Guideline
|
PCR Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
ofatumumab Sensitive: A2 - Guideline
|
ofatumumab Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
FCR Sensitive: A2 - Guideline
|
FCR Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
